The state of emergency was announced late Sunday that the US government’s health agency had invested $23 million in new manufacturing equipment at the Bayview plant in Maryland for the production of contaminated drugs. The company said in a statement: “In addition, Emergent hopes to reach an agreement with the US government and AstraZeneca to jointly agree to reduce the production of AstraZeneca’s COVID-19 vaccine raw materials.”
AstraZeneca did not immediately respond to a request for comment.
The official said the company has produced approximately 90 million doses that are ready or almost ready for use in the United States. AstraZeneca has not applied for an emergency authorization, which will allow the dose to be used in the United States, but said it could be approved before mid-April. At the same time, its vaccine has been used in dozens of other countries.
The closure of emergency facilities may disrupt supplies in these countries. The official said that when the company used Emergent in the United States, it relied on another Baltimore pharmaceutical factory operated by Catalent to produce vaccines for the COVAX Facility, a European, Japanese and international buying consortium. It is not clear whether the Catalent plant can take on additional work.
Last summer, AstraZeneca signed an agreement with the Trump administration to provide 300 million doses of vaccine. If authorized by the United States, it will become the fourth vaccine manufacturer to contribute to the US inventory. Officials said they hope to reach the goal of vaccinating most Americans who do not give AstraZeneca a dose this summer, but the company̵